## Emmanuel Chartier-kastler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9212314/publications.pdf

Version: 2024-02-01

74 papers 2,078 citations

331670 21 h-index 254184 43 g-index

81 all docs

81 docs citations

times ranked

81

1399 citing authors

#	Article	IF	CITATIONS
1	Sacral Neuromodulation with the InterStim System for Overactive Bladder: 3-Year Results from the French Prospective, Multicenter, Observational SOUNDS Study. European Urology Focus, 2022, 8, 1399-1407.	3.1	4
2	Outcomes of robotâ€essisted urinary sphincter implantation for male neurogenic urinary incontinence. BJU International, 2022, 129, 243-248.	2.5	5
3	Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter. World Journal of Urology, 2022, 40, 489-495.	2.2	2
4	Mid-term functional outcomes of extraperitoneal robot-assisted simple prostatectomy: a single centre experience. Journal of Robotic Surgery, 2022, , $1.$	1.8	0
5	Exploratory safety study of an umbilical cord derived urethral sling in bilateral pudendal nerves injuryâ€induced urinary incontinence in female rats. Neurourology and Urodynamics, 2022, 41, 777-786.	1.5	O
6	A Real-world Data Analysis of Intermittent Catheterization, Showing the Impact of Prelubricated Versus Hydrophilic Catheter Use on the Occurrence of Symptoms Suggestive of Urinary Tract Infections. European Urology Open Science, 2022, 38, 79-87.	0.4	1
7	The Virtue quadratic male sling for postradical prostatectomy urinary incontinence: 3â€Year outcome measurements and a predictive model of surgical outcome from a European prospective observational study. Neurourology and Urodynamics, 2022, 41, 456-467.	1.5	2
8	Dynamic evaluation of MRI-targeted, systematic and combined biopsy for prostate cancer diagnosis through 10Âyears of practice in a single institution. World Journal of Urology, 2022, 40, 1661-1668.	2.2	4
9	Hyaluronic Acid and Chondroitin Sulphate Treatment for Recurrent Severe Urinary Tract Infections due to Multidrug-Resistant Gram-Negative Bacilli in a Patient With Multiple Sclerosis: Case Report and Literature Review. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
10	Non-continent Urinary Diversion (Ileal Conduit) as Salvage Therapy in Patients With Refractory Lower Urinary Tract Dysfunctions due to Multiple Sclerosis: Results of a National Cohort From the French Association of Urology (AFU) Neurourology Committee and the French-speaking Neurourology Study Group (GENULF). Urology, 2022, 168, 216-221.	1.0	2
11	Neurogenic stress urinary incontinence management. From past to recent techniques: What have we learnt?. Progres En Urologie, 2022, , .	0.8	O
12	Sacral Neuromodulation with the InterStimâ,,¢ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study. European Urology Focus, 2021, 7, 1430-1437.	3.1	12
13	Preliminary assessment of patient and physician satisfaction with the use of teleconsultation in urology during the COVID-19 pandemic. World Journal of Urology, 2021, 39, 1991-1996.	2.2	51
14	Robot-assisted Supratrigonal Cystectomy and Augmentation Cystoplasty with Totally Intracorporeal Reconstruction in Neurourological Patients: Technique Description and Preliminary Results. European Urology, 2021, 79, 858-865.	1.9	13
15	Postoperative assessment of nosocomial transmission of COVID-19 after robotic surgical procedures during the pandemic. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 298.e7-298.e11.	1.6	6
16	Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: a single-Centre experience. Basic and Clinical Andrology, 2021, 31, 4.	1.9	7
17	How to treat neurogenic bladder and sexual dysfunction after spinal cord lesion. Revue Neurologique, 2021, 177, 589-593.	1.5	5
18	Long-term functional outcomes of artificial urinary sphincter (AMS 800â,,¢) implantation in women aged over 75Âyears and suffering from stress urinary incontinence caused by intrinsic sphincter deficiency. World Journal of Urology, 2021, 39, 3897-3902.	2.2	2

#	Article	IF	CITATIONS
19	Reprogramming Sacral Neuromodulation for Sub-Optimal Outcomes: Evidence and Recommendations for Clinical Practice. Neuromodulation, 2021, 24, 1247-1257.	0.8	6
20	Positive environmental impact of remote teleconsultation in urology during the COVID-19 pandemic in a highly populated area. Progres En Urologie, 2021, 31, 1133-1138.	0.8	0
21	Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex. European Urology Focus, 2020, 6, 522-530.	3.1	19
22	Urology surgical activity and COVIDâ€19: risk assessment at the epidemic peak: a Parisian multicentre experience. BJU International, 2020, 126, 436-440.	2.5	13
23	Neuroâ€Urology during the COVIDâ€19 pandemic: Triage and priority of treatments. Neurourology and Urodynamics, 2020, 39, 2011-2015.	1.5	8
24	Management of Female and Functional Urology Patients During the COVID Pandemic. European Urology Focus, 2020, 6, 1049-1057.	3.1	25
25	Robotâ€assisted laparoscopic artificial urinary sphincter insertion in women with stress urinary incontinence: a pilot singleâ€centre study. BJU International, 2020, 126, 722-730.	2.5	19
26	Outcomes of ileal conduit urinary diversion in patients with multiple sclerosis. Neurourology and Urodynamics, 2020, 39, 771-777.	1.5	7
27	Functional outcomes of synthetic tape and mesh revision surgeries: a monocentric experience. International Urogynecology Journal, 2019, 30, 805-813.	1.4	15
28	The Management of Urine Storage Dysfunction in the Neurological Patient. SN Comprehensive Clinical Medicine, 2019, 1, 160-182.	0.6	7
29	Management of urethrocutaneous fistulae complicating sacral and perineal pressure ulcer in neurourological patients: A national multicenter study from the Frenchâ€speaking Neuroâ€urology Study Group and the Neuroâ€urology committee of the French Association of Urology. Neurourology and Urodynamics, 2019, 38, 1713-1720.	1.5	4
30	Alphaâ€blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and metaâ€analysis. A report from the Neuroâ€Urology Promotion Committee of the International Continence Society (ICS). Neurourology and Urodynamics, 2019, 38, 1482-1491.	1.5	11
31	Botulinum Toxin Type A Injection After Failure of Augmentation Enterocystoplasty Performed for Neurogenic Detrusor Overactivity: Preliminary Results of a Salvage Strategy. The ENTEROTOX Study. Urology, 2019, 129, 43-47.	1.0	12
32	Are Slings Still the Gold Standard for Female Stress Urinary Incontinence?. European Urology Focus, 2019, 5, 315-316.	3.1	1
33	Desmopressin for treating nocturia in patients with multiple sclerosis: A systematic review: A report from the Neuroâ€Urology Promotion Committee of the International Continence Society (ICS). Neurourology and Urodynamics, 2019, 38, 563-571.	1.5	6
34	Neurogenic stress urinary incontinence: is there a place for Adjustable Continence Therapy (ACTâ,,¢ and) Tj ETQq0 388-395.	0 0 rgBT 1.9	/Overlock 1 12
35	Longâ€term functional outcomes of augmentation cystoplasty in adult spina bifida patients: A singleâ€center experience in a multidisciplinary team. Neurourology and Urodynamics, 2019, 38, 330-337.	1.5	17
36	Complications of non-continent cutaneous urinary diversion in adults with spinal cord injury: a retrospective study. Spinal Cord, 2018, 56, 856-862.	1.9	16

#	Article	IF	CITATIONS
37	Surgical management of the neurogenic bladder after spinal cord injury. World Journal of Urology, 2018, 36, 1569-1576.	2,2	22
38	International Continence Society best practice statement for use of sacral neuromodulation. Neurourology and Urodynamics, 2018, 37, 1823-1848.	1.5	113
39	Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and metaâ€analysis. A report from the Neuroâ€Urology Promotion Committee of the International Continence Society (ICS). Neurourology and Urodynamics, 2018, 37, 67-82.	1.5	15
40	Sacral neuromodulation and pregnancy: Results of a national survey carried out for the neuroâ€urology committee of the French Association of Urology (AFU). Neurourology and Urodynamics, 2018, 37, 792-798.	1.5	11
41	Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. Neurourology and Urodynamics, 2018, 37, 1386-1395.	1.5	50
42	Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism. Journal of Urology, 2018, 200, 875-880.	0.4	18
43	Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology, 2018, 91, e657-e665.	1.1	14
44	Stress urinary incontinence in female neurological patients: longâ€term functional outcomes after artificial urinary sphincter (AMS 800 <sup>TM</sup> ) implantation. Neurourology and Urodynamics, 2017, 36, 764-769.	1.5	31
45	Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and metaâ€analysis. BJU International, 2017, 119, 515-521.	2,5	26
46	Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder. Spinal Cord Series and Cases, 2017, 3, 17019.	0.6	3
47	Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder. Neuromodulation, 2017, 20, 825-829.	0.8	23
48	Sacral Neuromodulation: Standardized Electrode Placement Technique. Neuromodulation, 2017, 20, 816-824.	0.8	127
49	Pregnancy in spinal cord-injured women, a cohort study of 37 pregnancies in 25 women. Spinal Cord, 2017, 55, 167-171.	1.9	33
50	Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?. Research and Reports in Urology, 2017, Volume 9, 209-218.	1.0	5
51	Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity. European Journal of Physical and Rehabilitation Medicine, 2017, 53, 991-997.	2.2	2
52	Longâ€term complications of continent cutaneous urinary diversion in adult spinal cord injured patients. Neurourology and Urodynamics, 2016, 35, 1046-1050.	1.5	23
53	Risk of malignancy after augmentation cystoplasty: A systematic review. Neurourology and Urodynamics, 2016, 35, 675-682.	1.5	62
54	Management of neurogenic bladder in patients with multiple sclerosis. Nature Reviews Urology, 2016, 13, 275-288.	3.8	107

#	Article	IF	Citations
55	Re: Xavier Biardeau, JérÃ′me Rizk, François Marcelli, Vincent Flamand. Robot-assisted Laparoscopic Approach for Artificial Urinary Sphincter Implantation in 11 Women with Urinary Stress Incontinence: Surgical Technique and Initial Experience. Eur Urol 2015;67:937–42. European Urology, 2016, 69, e45-e46.	1.9	1
56	Control Cross-sectional Study Evaluating an Antibiotic Prevention Strategy in 30 Pregnancies Under Clean Intermittent Self-catheterization and Review of Literature. Urology, 2016, 91, 58-63.	1.0	9
57	Functional outcomes of adjustable continence therapy (ACTâ,,¢) balloons in women aged >80Âyears and suffering from stress urinary incontinence caused by intrinsic sphincter deficiency. World Journal of Urology, 2015, 33, 1897-1903.	2.2	8
58	Re: Completely Intracorporeal Robotic-assisted Laparoscopic Augmentation Enterocystoplasty With Continent Catheterizable Channel (Urology 2014;84:1314-1318). Urology, 2015, 86, 205.	1.0	0
59	Comparison of functional outcomes with purely laparoscopic sacrocolpopexy and robot-assisted sacrocolpopexy in obese women. Progres En Urologie, 2014, 24, 1106-1113.	0.8	13
60	Artificial Urinary Sphincter AMS 800â,,¢ in Malesâ€"Can We Explain Residual Leaks When Sitting?. Journal of Urology, 2014, 192, 483-487.	0.4	7
61	Treatment of Neurogenic Stress Urinary Incontinence Using an Adjustable Continence Device: 4-Year Followup. Journal of Urology, 2012, 188, 2274-2280.	0.4	35
62	Functional Outcomes After Management of End-stage Neurological Bladder Dysfunction With Ileal Conduit in a Multiple Sclerosis Population: A Monocentric Experience. Urology, 2011, 78, 937-941.	1.0	36
63	Botulinum neurotoxin A for male lower urinary tract symptoms. Current Opinion in Urology, 2011, 21, 13-21.	1.8	12
64	Artificial urinary sphincter (AMS 800) implantation for women with intrinsic sphincter deficiency: a technique for insiders?. BJU International, 2011, 107, 1618-1626.	2.5	66
65	Safety of a new compact catheter for men with neurogenic bladder dysfunction: a randomised, crossover and open-labelled study. Spinal Cord, 2011, 49, 844-850.	1.9	13
66	Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retention. Neurourology and Urodynamics, 2011, 30, 21-31.	1.5	68
67	ES1 Management of male LUTS: how concepts are evolving!. Japanese Journal of Urology, 2011, 102, 73.	0.1	0
68	Laparoscopic Approach for Artificial Urinary Sphincter Implantation in Women with Intrinsic Sphincter Deficiency Incontinence: A Single-Centre Preliminary Experience. European Urology, 2010, 57, 499-505.	1.9	66
69	Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and nonâ€obstructive urinary retention: >10â€∫years of clinical experience. BJU International, 2008, 101, 417-423.	2.5	34
70	A novel technique to achieve cutaneous continent urinary diversion in spinal cord-injured patients unable to catheterize through native urethra. Spinal Cord, 2008, 46, 305-310.	1.9	31
71	Does Management of Erectile Dysfunction after Radical Prostatectomy Meet Patients' Expectations? Results of a National Survey (REPAIR) by the French Urological Association. Journal of Sexual Medicine, 2008, 5, 693-704.	0.6	42
72	LUTS/BPH in clinical practice: the importance of nocturia and quality of sleep. BJU International, 2006, 98, 3-8.	2.5	13

#	Article	IF	CITATIONS
73	Pharmacokinetic profile of tamsulosin OCAS. BJU International, 2006, 98, 9-12.	2.5	7
74	BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDY. Journal of Urology, 2005, 174, 196-200.	0.4	532